Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Lanier

Plastic Surgery Chicago, IL Medical Doctor

NPI 1871856690 CMS profile 266919

680 N Lake Shore Dr Ste 924, Chicago, IL 60611

Open in the dashboard

General payments

$16,788

21 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Lanier of Chicago, IL is reported in the CMS Open Payments database as having received $16,788 across 21 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $306 2
2024 General $42 1
2022 General $1,418 6
2021 General $1,200 1
2020 General $255 2
2019 General $13,566 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Lanier
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Steven Lanier were reported at $306. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Steven Lanier Plastic Surgery median Middle half National median
2019 $13,566 $371 $122–$1,483 $163
2020 $255 $158 $52–$438 $114
2021 $1,200 $249 $87–$752 $132
2022 $1,418 $274 $102–$793 $149
2023 $0 $299 $113–$891 $160
2024 $42 $361 $124–$1,062 $164
2025 $306 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $10,000 1 payment
  2. Medwest Associates $2,435 5 payments
  3. Elite Orthopedics, LLC $2,051 1 payment
  4. Acumed LLC $1,530 5 payments
  5. Medartis Inc. $538 3 payments
  6. Integra LifeSciences Corporation $113 2 payments
  7. Stryker Corporation $42 1 payment
  8. Djo, LLC $38 1 payment
  9. AxoGen $22 1 payment
  10. Musculoskeletal Transplant Foundation Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $10,000 1 payment
  2. Education $4,451 3 payments
  3. Travel and Lodging $1,320 3 payments
  4. Food and Beverage $1,017 14 payments
Products named General payments · program years 2019–2025
  1. Acu-Loc Wrist Plating System $1,530 5 payments
  2. Acutrak Headless Compression Screw System $1,382 4 payments
  3. Hand Fracture System $1,382 4 payments
  4. Osteotomy System $717 2 payments
  5. Total Wrist Fusion Plating System $717 2 payments
  6. APTUS Ortho $376 2 payments
  7. APTUS Ortho $162 1 payment
  8. Elbow Plating System $147 1 payment
  9. Anatomic Radial Head System $147 1 payment
  10. AMNIOEXCEL $113 2 payments
  11. Other $555 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

29

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$115

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

100%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$56,115

Of which drugs: $302

Medicare patients

198

Average age 75

Services billed

2,947

136 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 67%
High blood pressure 66%
Diabetes 32%
Ischemic heart disease 26%
Osteoporosis 25%
Chronic kidney disease 21%
Depression 21%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 39 2,400 $242
Injection, methylprednisolone acetate, 40 mg J1030 Office 13 20 $60

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record